FINAL RESULTS OF A MULTICENTRE PHASE II TRIAL EVALUATING CETUXIMAB IN COMBINATION WITH FOLFIRINOX AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS

被引：0
|
作者：
Samalin, E. [1 ]
Desseigne, F. [2 ]
Thezenas, S. [1 ]
Bibeau, F. [1 ]
Viret, F. [3 ]
Mineur, L. [4 ]
Assenat, E. [1 ]
Bleuse, J. [1 ]
Portales, F. [1 ]
Crapez, E. [1 ]
Ychou, M. [1 ]
机构：
[1] CRLC Val Aurelle, Montpellier, France
[2] Ctr Leon Berard, F-69373 Lyon, France
[3] Inst J Paoli I Calmettes, F-13009 Marseille, France
[4] Inst St Catherine, Avignon, France
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [31] Final efficacy and safety findings from a phase II trial of capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC)
    Patt, Yehuda
    Liebmann, James
    Diamandidis, Dimitrios
    Eckhardt, Gail
    Javle, Milind
    Justice, Glen
    Keiser, Leroy W.
    Lee, Fa-Chyi
    Miller, William
    Lin, Edward
    ANNALS OF ONCOLOGY, 2004, 15 : 88 - 88
  • [32] Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients
    Bécouarn, Y
    Ychou, M
    Ducreux, M
    Borel, C
    Bertheault-Cvitkovic, F
    Seitz, JF
    Nasca, S
    Nguyen, TD
    Paillot, B
    Raoul, JL
    Duffour, J
    Fandi, A
    Dupont-André, G
    Rougier, P
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2739 - 2744
  • [33] Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results from the CRYSTAL trial
    Ciardiello, Fortunato
    Lenz, Heinz-Josef
    Kohne, Claus-Henning
    Heinemann, Volker
    Tejpar, Sabine
    Esser, Regina
    Beier, Frank
    Stroh, Christopher
    Duecker, Klaus
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [34] Vinorelbine and capecitabine combination as first-line treatment in patients with metastatic breast cancer: Final results of a multicentric trial in Egypt
    Elghazaly, H.
    Tawfik, H.
    Mahrous, M.
    Meshref, M. M.
    Sakr, A.
    Haddad, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer
    Vrdoljak, Eduard
    Omrcen, Tomislav
    Boban, Marijo
    Hrabar, Andina
    ANTI-CANCER DRUGS, 2011, 22 (02) : 191 - 197
  • [36] Phase III results for first-line treatment for metastatic colorectal cancer
    Kotsiliti, Eleni
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (02) : 65 - 65
  • [37] Phase III results for first-line treatment for metastatic colorectal cancer
    Eleni Kotsiliti
    Nature Reviews Gastroenterology & Hepatology, 2023, 20 : 65 - 65
  • [38] Efficacy and safety of XELIRI plus cetuximab versus XELOX plus cetuximab in first-line treatment of metastatic colorectal cancer (mCRC)
    Ocvirk, J.
    Boc, M.
    Rebersek, M.
    Mesti, T.
    Ebert, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial
    Van Cutsem, E.
    Nowacki, M.
    Lang, I.
    Cascinu, S.
    Shchepotin, I.
    Maurel, J.
    Rougier, P.
    Cunningham, D.
    Nippgen, J.
    Koehne, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC)
    Van Cutsem, E.
    Bodoky, G.
    Kyung Roh, J.
    Folprecht, G.
    Park, Y. S.
    Van Laethem, J. L.
    Raoul, J. L.
    Ciardiello, F.
    Lebrun, P.
    Rougier, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 235 - 235
12345